Hyderabad News Desk

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Myeloid Leukemia pipeline constitutes 260+ key companies continuously working towards developing 260+ Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

“Acute Myeloid Leukemia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Myeloid Leukemia Market.

 

Some of the key takeaways from the Acute Myeloid Leukemia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Acute Myeloid Leukemia treatment therapies with a considerable amount of success over the years. 
• Acute Myeloid Leukemia companies working in the treatment market are SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, and others, are developing therapies for the Acute Myeloid Leukemia treatment 

• Emerging Acute Myeloid Leukemia therapies in the different phases of clinical trials are- GNC 035, JSP 191, ONC201, AK117, Tamibarotene, TCB008, Elzonris, Orca T, Magrolimab+ azacitidine, Uproleselan, Fosciclopirox + Cytarabine, CPX351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, and others are expected to have a significant impact on the Acute Myeloid Leukemia market in the coming years.   
• In January 2023, Preclinical findings demonstrating the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123 was published in Nature Biotechnology, according to a statement from Innate Pharma SA.
• In January 2023, According to a news statement from Jubilant Therapeutics, the FDA designated JBI-802 as an orphan medication for patients with acute myeloid leukemia (AML) and small cell lung cancer (SCLC).
• In January 2022, Astex Pharmaceuticals, Inc. declared that the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the treatment of acute myeloid leukemia (AML) has been given orphan-drug designation (ODD) by the European Commission (EC).
• In August 2022, Announcing that it will keep revising its estimate for the mid-2023 survival events trigger for its pivotal Phase 3 trial assessing uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML), GlycoMimetics said.

 

Acute Myeloid Leukemia Overview

About 80 percent of occurrences of leukemia in adults are acute myeloid leukemia (AML), making it the most prevalent kind in this population. The condition is typified by the clonal proliferation of immature “blast cells” in the bone marrow and peripheral circulation, leading to inefficient erythropoiesis and bone marrow failure.

 

Get a Free Sample PDF Report to know more about Acute Myeloid Leukemia Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight

 

Emerging Acute Myeloid Leukemia Drugs Under Different Phases of Clinical Development Include:

• GNC 035: SystImmune
• JSP 191: Jasper Therapeutics
• ONC201: Chimerix
• AK117: Akeso Biopharma Co., Ltd.
• Tamibarotene: Syros Pharmaceuticals
• TCB008: TC Biopharm
• Elzonris: Stemline Therapeutics
• Orca T: Orca Bio
• Magrolimab+ azacitidine: Gilead Sciences
• Uproleselan: GlycoMimetics
• Fosciclopirox + Cytarabine: CicloMed LLC
• CPX351: Jazz Pharmaceuticals
• Minnelide: Minneamrita Therapeutics LLC
• SNDX-5613: Syndax Pharmaceuticals
• ASTX727: Astex Pharmaceuticals, Inc.
• KPT-9274: Karyopharm Therapeutics Inc
• SAR445419: Sanofi

 

Acute Myeloid Leukemia Route of Administration

Acute Myeloid Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

 

Acute Myeloid Leukemia Molecule Type

Acute Myeloid Leukemia Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Acute Myeloid Leukemia Pipeline Therapeutics Assessment

• Acute Myeloid Leukemia Assessment by Product Type
• Acute Myeloid Leukemia By Stage and Product Type
• Acute Myeloid Leukemia Assessment by Route of Administration
• Acute Myeloid Leukemia By Stage and Route of Administration
• Acute Myeloid Leukemia Assessment by Molecule Type
• Acute Myeloid Leukemia by Stage and Molecule Type

 

DelveInsight’s Acute Myeloid Leukemia Report covers around 260+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further Acute Myeloid Leukemia product details are provided in the report. Download the Acute Myeloid Leukemia pipeline report to learn more about the emerging Acute Myeloid Leukemia therapies

 

Some of the key companies in the Acute Myeloid Leukemia Therapeutics Market include:

Key companies developing therapies for Acute Myeloid Leukemia are – CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, Polaris Group, Bio-Path Holdings, Inc., Chordia Therapeutics, Inc., Theradex, BioTheryX, Inc., Precigen, Inc, Eli Lilly and Company, Bayer, Takeda, Meryx, Inc., 2seventy bio, JW Pharmaceutical, Telios Pharma, and others.

 

Acute Myeloid Leukemia Pipeline Analysis:

The Acute Myeloid Leukemia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Myeloid Leukemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukemia Treatment.
• Acute Myeloid Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Myeloid Leukemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Acute Myeloid Leukemia drugs and therapies

 

Acute Myeloid Leukemia Pipeline Market Drivers

• Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important factors that are fueling the Acute Myeloid Leukemia Market.

 

Acute Myeloid Leukemia Pipeline Market Barriers

• However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Acute Myeloid Leukemia Market growth.

 

Scope of Acute Myeloid Leukemia Pipeline Drug Insight    

• Coverage: Global
• Key Acute Myeloid Leukemia Companies: SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, and others
• Key Acute Myeloid Leukemia Therapies: GNC 035, JSP 191, ONC201, AK117, Tamibarotene, TCB008, Elzonris, Orca T, Magrolimab+ azacitidine, Uproleselan, Fosciclopirox + Cytarabine, CPX351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, and others
• Acute Myeloid Leukemia Therapeutic Assessment: Acute Myeloid Leukemia current marketed and Acute Myeloid Leukemia emerging therapies
• Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia market drivers and Acute Myeloid Leukemia market barriers 

 

Request for Sample PDF Report for Acute Myeloid Leukemia Pipeline Assessment and clinical trials

 

Table of Contents

1. Acute Myeloid Leukemia Report Introduction

2. Acute Myeloid Leukemia Executive Summary

3. Acute Myeloid Leukemia Overview

4. Acute Myeloid Leukemia- Analytical Perspective In-depth Commercial Assessment

5. Acute Myeloid Leukemia Pipeline Therapeutics

6. Acute Myeloid Leukemia Late Stage Products (Phase II/III)

7. Acute Myeloid Leukemia Mid Stage Products (Phase II)

8. Acute Myeloid Leukemia Early Stage Products (Phase I)

9. Acute Myeloid Leukemia Preclinical Stage Products

10. Acute Myeloid Leukemia Therapeutics Assessment

11. Acute Myeloid Leukemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Myeloid Leukemia Key Companies

14. Acute Myeloid Leukemia Key Products

15. Acute Myeloid Leukemia Unmet Needs

16 . Acute Myeloid Leukemia Market Drivers and Barriers

17. Acute Myeloid Leukemia Future Perspectives and Conclusion

18. Acute Myeloid Leukemia Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services